Mutating the antibody's Fc region to increase its affinity to the activatory human Fcγ receptors, particularly FcγRIIIA and FcγRIIA, represents a clinically validated option to increase ADCC and ADCP, both having a crucial role in tumor elimination by immune cells (20, 26). The gene discussed is FCGR3A; the disease is neoplasm.